Canada’s Drug Agency (CDA-AMC) recommends that Tezspire be reimbursed by public drug plans as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery if certain conditions are met.
